Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 24

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 24
---
 that, when transplanted in myelin -deficientanimals, have regenerated the myelin coating. These studies contributed to the development of a suspension culture technology for hESC which can then be used to produce differentiated human cells such as insulin -producingpancreatic beta cells and nerve myelinating cells. Alongside his research and development activity, Prof. Revel is deeply involved in the ethics of science and biotechnology, and served as Chairman of the Israel National Bioethics Council and was a member of the International Bioethics Committee of UNESCO. Prof. Revel was the recipient of the Israel Prize for medical research, the EMET Prize for biotechnology, and

is a member of the Israel Academy of Science and Humanities. He has been a member of Israel’s National Committee for Biotechnology, serving for three years as its Chairman. Professor Revel holds M.D. and Ph.D. degrees from the University of Strasbourg, France. Mr. Eran Iohan:Mr.Eran Iohan has served as a director of Kadimastem since October of 2022. Mr.Iohan brings with him over 20 years of financial, accounting, and managerial experience, leading IPOs, follow -oninvestments, and complex transactions in Israel and the U.S. for technology and bio -technologycompanies. Since December 2019, Mr.Iohan has been a director of My Green Fields. Since January 2019, Mr.Iohan has also served as the Founder of Thin Places. From March 2021 until June 2023, he served as Chief Financial Officer at TurboGen. From January 2007 to June 2019, Mr.Iohan was a Partner and Entertainment & Media Industry Leader at PwC Israel, and he served as a staff member in various roles at PwC Israel from January 1998 to December 2006. Mr.Iohan is a Certified Public Accountant (CPA) in Israel and the U.S. (California). He has a B.A. in Accounting and Economics, and an MBA in Finance and Information Technologies, both from Tel -AvivUniversity, Israel. Ms. Liora Oren:Ms. Liora Oren has served as a director of Kadimastem and as Chair of the audit committee of Kadimastem since September 2022. Ms. Oren brings with her 20 years of financial experience from various companies including the Bio -TechIndustry and multinational companies traded on the NYSE and the Nasdaq. Ms.